Compare NNBR & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | PYPD |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 76.4M |
| IPO Year | 1994 | 2020 |
| Metric | NNBR | PYPD |
|---|---|---|
| Price | $1.55 | $4.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 323.4K | 78.8K |
| Earning Date | 03-04-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $424,005,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $2.30 |
| 52 Week High | $3.52 | $5.12 |
| Indicator | NNBR | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 45.68 |
| Support Level | $1.46 | $4.52 |
| Resistance Level | $1.65 | $5.12 |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 48.00 | 11.49 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.